ResearcherJohns Hopkins UniversityActive in the last 2 years
Jianxin Wang
Matched on ORCID iD 0000-0002-6583-1281; OpenAlex author ID A5061708117. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper
Papers 5
- Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. Co-author DOI 10.1172/jci.insight.182766↗
- Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Co-author DOI 10.1016/j.canlet.2023.216366↗
- Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. First author DOI 10.1053/j.gastro.2022.06.027↗
- CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
- Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Co-author DOI 10.1016/j.cdtm.2020.01.002↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lei Zheng · 4 shared papers, 2020–2023 · strength 0.52
- Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
- Paper Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. DOI 10.1016/j.cdtm.2020.01.002↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Sophia Y. Chen · 3 shared papers, 2022–2024 · strength 0.47
- Paper Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. DOI 10.1172/jci.insight.182766↗
- Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
- Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
- Heng‐Chung Kung · 2 shared papers, 2023–2024 · strength 0.35
- Nan Niu · 3 shared papers, 2020–2022 · strength 0.35
- Paper Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. DOI 10.1016/j.cdtm.2020.01.002↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
- Keyu Li · 3 shared papers, 2020–2022 · strength 0.35
- Paper Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. DOI 10.1016/j.cdtm.2020.01.002↗
- Paper Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. DOI 10.1053/j.gastro.2022.06.027↗
- Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
- Kenji Fujiwara · 2 shared papers, 2022–2023 · strength 0.28
- William L. Hwang · 1 shared paper, 2024 · strength 0.18
- William R. Burns · 1 shared paper, 2024 · strength 0.18
- Lei Zheng · 1 shared paper, 2024 · strength 0.18
- Jun Yu · 1 shared paper, 2023 · strength 0.17
- Tengyi Zhang · 1 shared paper, 2023 · strength 0.17
- Xubao Liu · 1 shared paper, 2020 · strength 0.12
- Chunhui Yuan · 1 shared paper, 2020 · strength 0.12
- Ding Ding · 1 shared paper, 2022 · strength 0.12
- Jin Peng He · 1 shared paper, 2022 · strength 0.12
- Brian T. Herbst · 1 shared paper, 2022 · strength 0.12
- Stephen T. Muth · 1 shared paper, 2022 · strength 0.12
- May Tun Saung · 1 shared paper, 2022 · strength 0.12
- Andrew Eugene Hendifar · 1 shared paper, 2022 · strength 0.12
- Junke Wang · 1 shared paper, 2022 · strength 0.12
- Pan Li · 1 shared paper, 2022 · strength 0.12
- Noah S Rozich · 1 shared paper, 2022 · strength 0.12
- Jun-Ke Wang · 1 shared paper, 2022 · strength 0.12
- Richard Andrew Burkhart · 1 shared paper, 2022 · strength 0.12
- Yao Xu · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.